Schuylkill Financial LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,018 shares of the company’s stock, valued at approximately $992,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in shares of iShares U.S. Pharmaceuticals ETF by 0.3% during the first quarter. Royal Bank of Canada now owns 101,984 shares of the company’s stock worth $7,197,000 after buying an additional 325 shares during the period. Goldman Sachs Group Inc. increased its position in iShares U.S. Pharmaceuticals ETF by 4.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 104,815 shares of the company’s stock valued at $7,396,000 after acquiring an additional 4,815 shares during the period. JPMorgan Chase & Co. raised its stake in iShares U.S. Pharmaceuticals ETF by 781.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 110,936 shares of the company’s stock valued at $7,271,000 after acquiring an additional 98,352 shares during the last quarter. Raymond James Financial Inc. raised its stake in iShares U.S. Pharmaceuticals ETF by 3.2% during the 2nd quarter. Raymond James Financial Inc. now owns 63,564 shares of the company’s stock valued at $4,166,000 after acquiring an additional 1,955 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in iShares U.S. Pharmaceuticals ETF by 491.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 23,658 shares of the company’s stock worth $1,550,000 after acquiring an additional 19,661 shares during the period.
iShares U.S. Pharmaceuticals ETF Trading Down 0.7%
iShares U.S. Pharmaceuticals ETF stock opened at $104.68 on Friday. The stock has a 50 day moving average of $102.63 and a two-hundred day moving average of $93.91. iShares U.S. Pharmaceuticals ETF has a twelve month low of $69.02 and a twelve month high of $108.66. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 17.75 and a beta of 0.49.
iShares U.S. Pharmaceuticals ETF Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Read More
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
